Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Position Increased by Private Advisor Group LLC

Private Advisor Group LLC lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 18.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,135 shares of the medical device company’s stock after acquiring an additional 939 shares during the period. Private Advisor Group LLC’s holdings in Tandem Diabetes Care were worth $221,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Brooklyn Investment Group acquired a new stake in Tandem Diabetes Care in the third quarter worth about $28,000. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at about $29,000. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at about $52,000. Venturi Wealth Management LLC increased its holdings in Tandem Diabetes Care by 5,955.9% in the fourth quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after buying an additional 2,025 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Tandem Diabetes Care in the third quarter worth approximately $105,000.

Tandem Diabetes Care Trading Down 2.0 %

NASDAQ:TNDM opened at $18.72 on Friday. Tandem Diabetes Care, Inc. has a fifty-two week low of $18.27 and a fifty-two week high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock has a market capitalization of $1.24 billion, a PE ratio of -9.70 and a beta of 1.32. The business’s 50-day simple moving average is $33.55 and its 200-day simple moving average is $35.75.

Analyst Ratings Changes

Several brokerages have commented on TNDM. Robert W. Baird lowered their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Barclays reduced their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Sanford C. Bernstein lowered Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Morgan Stanley lowered Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $45.00 to $22.00 in a research note on Wednesday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $63.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.38.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.